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Abstract 22 
Inflammatory bowel disease (IBD) may develop due to an immunogenic response to commensal gut 23 
microbiota triggered by environmental factors in the genetically susceptible host. Isotretinoin as 24 
applied in the treatment of severe acne has been variably associated with IBD but prior treatment 25 
with antibiotics, also associated with IBD development, confounds confirmation of this association. 26 
We investigated the effects of doxycycline, metronidazole, which are frequently used in the 27 
treatment of acne and IBD, respectively, and isotretinoin on murine gut (fecal) microbiota after 2 28 
weeks’ treatment and after a 4-week recovery period. Fecal microbiota composition was assessed by 29 
16S rRNA gene sequencing on the GS-FLX 454 platform with primers directed against the variable 30 
regions V1-V2. Doxycycline showed a modest effect on bacterial richness and evenness but 31 
pronounced persistent and significant effects on the abundance of certain operational taxonomic 32 
units compared to the control group. In contrast, metronidazole induced a pronounced reduction in 33 
diversity post treatment but these effects did not persist during the recovery period. This study 34 
demonstrates differential effects of antibiotics on the gut microbiota with doxycycline, unlike 35 
metronidazole, mediating long-term changes in the murine gut microbiota. Isotretinoin had no 36 
significant effect on the fecal microbiota.  37 
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Highlights 38 
•  Medications may modulate the gut microbiota favoring later development of IBD 39 
• IBD is associated with prior antibiotic use. An impact of isotretinoin is uncertain. 40 
• Isotretinoin, had no significant impact on community composition or diversity  41 
• Metronidazole, induced a significant drop in diversity that recovered within 4 weeks. 42 
• Doxycycline had modest direct effects but a lasting impact on composition at OTU level. 43 
  44 
Key Words metronidazole, doxycycline, isotretinoin, dysbiosis, IBD, gut microbiota composition, 45 
colitis, antibiotics 46 
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1. Introduction 51 
The microbiota of the gastrointestinal tract has a profound influence on host physiology and nutrition, 52 
including protection of epithelial cell barrier [1] and regulation of host fat storage [2]. Associations 53 
between alterations in gut microbiota composition and a wide variety of pathologic conditions 54 
including inflammatory bowel disease (IBD), obesity and associated insulin resistance, asthma, allergy, 55 
cardiovascular disease and neurologic disorders [3] have been shown over the last decade. Yet, in 56 
most cases, it is not clear whether alterations of the gut microbiota are causal or secondary to the 57 
disease. However, in recent years an increasing body of evidence rather suggests the former, including 58 
IBD-like microbial alterations in healthy siblings [4] as well as an increasing degree of hallmarks of 59 
dysbiosis in correlation to the amount of genetic alterations [5]. A breakdown of host-microbial 60 
mutualism triggered by environmental factors or genetic predisposition leading to dysbiosis and an 61 
inappropriate and progressive immune response to the commensal gut microbiota [2] is assumed to 62 
be causal for the pathogenesis of inflammatory bowel diseases (IBD) [6, 7]. 63 
The specific pathogenesis of IBD remains unclear, so far, but appears to be multifactorial. To 64 
date, genome-wide association studies have identified 201 IBD susceptibility loci [8], affecting genes 65 
involved in epithelial barrier function, mucosal immune response, autophagy and immune 66 
regulation; a major fraction of these genes participate in the sensing of microbial products or affect 67 
defense signaling in response to gut microbes [1]. However, host genotype explains only up to 20-68 
25% of IBD heritability overall, and 30-40% of CD and up to 10% of UC incidence [9]. Environmental 69 
factors potentially contributing to IBD include diet, appendectomy, smoking, breastfeeding, personal 70 
hygiene and medication(s) [6]. 71 
Evidence is increasing that antibiotics can influence established IBD, as well as on IBD flares, 72 
and that they increase the risk of developing IBD in both children and adults [10-12]. However, 73 
remarkably few studies have investigated the effect of individual antibiotics, the underlying 74 
mechanisms or whether there are any long-term ‘persistent’ effects of antibiotics on the gut 75 
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microbiota [13-15]. Furthermore, a number of reports have claimed a potential association between 76 
isotretinoin, a non-antimicrobial treatment for severe acne, and development of IBD [16, 17], 77 
although a causal role has not been established [18, 19]. Isotretinoin is typically used in patients 78 
unresponsive to antibiotics [11], thus, any causal relationship with IBD development is difficult to 79 
confirm due to confounding antibiotic treatment. 80 
In this study, we investigated the effects of doxycycline (used to treat acne but associated with the 81 
development of IBD), metronidazole (one of the preferred antibiotic agents for IBD patients), and 82 
isotretinoin on murine gut (fecal) microbiota after 2 weeks’ treatment (immediate effects) and after 83 
a 4-week recovery period (long-term effects). Our investigations aim at identifying possible 84 
environmental stressors that might have an immediate or persistent impact on gut microbiota 85 
composition that might have an impact on gut homeostasis and contribute to development of 86 
inflammatory bowel disease later on.  87 
 88 
  89 
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2. Methods 90 
2.1 Animals and treatment 91 
In total, 164 female BALB/c mice were purchased from Charles River Laboratories (Germany) and 92 
housed in individually ventilated cages per treatment in the animal facility of the University Hospital 93 
Zurich, with access to rodent chow and water ad libitum (Figure 1A). Isotretinoin (30 mg/ml, F- 94 
Hoffmann-La Roche Ltd, Basel, Switzerland), vehicle (rapeseed oil, Brassica rapa, Sigma-Aldrich, St. 95 
Louis, MO, United States), metronidazole (107 mg/kg, Sigma Aldrich), doxycycline (43 mg/kg, Sigma 96 
Aldrich) and water were administered orally for two weeks. For details of study design, animals per 97 
group and sample collection see Figure 1. 98 
2.2 Sample preparation and 16S rRNA gene sequencing 99 
Total Genomic DNA from fecal samples was extracted using the PowerLyzer® PowerSoil® DNA 100 
Isolation Kit (Mo Bio Laboratories, Inc., France) according to the manufacturer’s instructions. The 101 
hypervariable regions 1 to 2 (V1–2) of the 16S rRNA gene were amplified from isolated genomic DNA 102 
using bacterial specific primer Pyro_27F (Adaptor B) and the barcoded reverse primer MIDx_338R 103 
(Adaptor A) (Supplementary Table 1). The primer pair had specific 8 base long identifiers (barcode), a 104 
linker sequence and sequencing adaptors as described earlier [20] (Supplementary Table 1).  105 
Amplification reactions were performed in a total volume of 50 µl containing 5x HF buffer (New 106 
England Biolabs, Ipswich, MA, USA), 10 mM deoxynucleotide triphosphate (illustra solution dNTP GE 107 
Healthcare, Pittsburgh, PA, USA), 2’000 U/ml Phusion® High-Fidelity DNA Polymerase (New England 108 
Biolabs, Ipswich, MA, USA), 10 µM Forward Primer Pyro_27F, 10 µM Reverse Primer MIDx_338R 109 
(Metabion, Planegg, Germany) and 50 ng DNA diluted in DNA-free water. 110 
PCR amplification was performed on a Thermocycler from SensoQuest with the following 111 
cycling conditions employed: 98°C for 3 minutes, 25 cycles at 98°C each for 10 seconds, 55°C for 30 112 
seconds, 72°C for 30 seconds and a final extension at 72°C for 10 minutes. Amplicons were run on a 113 
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2% agarose gel to allow isolation of the bands at 400 base pairs with extraction of amplicons 114 
performed with MinElute Gel Extraction Kit (Qiagen AG, Hombrechtikon, Switzerland) and eluted in 115 
55 µl DNase-free water. PCR products were pyrosequenced on the GS-FLX 454 platform at the 116 
Functional Genomic Center Zurich (Zurich, Switzerland) and at Microsynth (Balgach, Switzerland). 117 
2.3 Bioinformatics 118 
Raw 454 sequencing reads were de-noised and de-multiplexed using the Amplicon Noise software 119 
[21] as implemented in mothur [22] and based on mothur's Standard Operating Procedure for 454 120 
data [23]. To filter for chimeric sequences, the UCHIME algorithm [24] was run in both de novo and 121 
reference-based mode against a custom, global database of non-chimeric 16S sequences, as 122 
described previously [25]. Sequences flagged as 'chimeric' by both algorithms were removed from 123 
the dataset. Sequences were aligned against a secondary structure-aware model of the bacterial 16S 124 
rRNA gene (provided in the package ssu-align) using Infernal [26, 27]. Alignments were pruned to 125 
positions 100-357 in the reference model, and sequences that aligned poorly within this range (≥ 126 
10% unaligned bases or ≥ 20% gaps) were excluded from further analyses. After this filtering, the 127 
dataset contained 2’098’361 aligned sequences of length 257 nt. 128 
Sequences were clustered into operational taxonomic units (OTUs) at different similarity 129 
thresholds according to the average linkage algorithms as implemented in hpc-clust [28]. Both 130 
algorithms have been shown to provide consistent OTUs that approximate clustering of full-length 131 
sequences for the 16S rRNA gene sub-regions targeted in this study [25]. Sequence taxonomy was 132 
inferred using the ribosomal database project (RDP) Classifier [29] with default parameters. A 133 
maximum likelihood phylogenetic tree of unique sequences was obtained using FastTree2 employing 134 
default parameters [30]. Community diversity calculations and statistical analyses were performed in 135 
R [31], and in particular using the packages phyloseq [32], vegan [33] and edgeR [34]. All data used in 136 
this study are available online (National Center for Biotechnology Information (NCBI) Sequence Read 137 
Archive project SRP065320). 138 
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2.4 Community richness and evenness 139 
Estimates of inter-group and inter-mouse community richness and evenness were assessed per 140 
sample in terms of Chao's Abundance-based Coverage Estimator (ACE), the Gini-Simpson Index and 141 
the Shannon entropy index; calculation was based on OTUs clustered at 98% average linkage 142 
sequence similarity. 143 
2.5 Detection of individual differentially abundant OTUs (taxonomic analysis) 144 
To investigate the fine-scale community composition at the level of individual OTUs, we used the R 145 
package edgeR [34], as suggested previously [35]. This approach provides a statistical framework for 146 
comparisons between treated and non-treated groups by quantifying the abundances of individual 147 
OTUs found in each dataset. Representative sequences for every OTU per treatment and time point 148 
that was significantly different from the respective control group was blasted against the NCBI 16S 149 
rRNA reference database for fine-scale taxonomic annotation, employing the following thresholds: 150 
|log2(fold change)|>1, FDR <0.001 and match-ID >97%. 151 
 152 
 153 
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3. Results 154 
3.1 Immediate and long-term effects on microbiota phylum-level composition 155 
The microbiota composition of all 164 animals at phylum level, across all time points and treatment 156 
conditions of the study, were as generally expected for murine gut microbiota (Figure 2A). The 157 
dominant phyla were Bacteroidetes and Firmicutes, with very low abundances of Proteobacteria and 158 
Actinobacteria; approximately 10% of sequences per sample could not be confidently classified at 159 
phylum level when using the RDP Classifier with default parameters. 160 
In fecal samples collected prior to treatment start, there were no notable differences evident 161 
between the treatment and vehicle control groups for either the antibiotics (metronidazole, 162 
doxycycline and water; multivariate analysis of variance on phylum-level taxonomic composition, F = 163 
2.01, P-value = 0.0673) or isotretinoin (isotretinoin and rapeseed oil; F = 0.407, P-value = 0.802) 164 
treatment regimen. Following 2 weeks of treatment, microbiota composition at phylum level 165 
differed significantly between the antibiotic groups (F = 3.87, P-value = 0.002); this difference 166 
persisted after the recovery period (F = 2.62, P-value = 0.016). In contrast, isotretinoin treatment did 167 
not induce significant changes from pre-treatment composition either immediately after treatment 168 
(F = 1.01, P-value = 0.419), or after the recovery period (F = 1.55, P-value = 0.25). Notably, mice 169 
treated with water or antibiotics showed generally elevated Firmicutes levels after the recovery 170 
period when compared to mice treated with isotretinoin or rapeseed oil vehicle. 171 
Changes in community composition at phylum level over time within a treatment group were 172 
statistically significant for mice treated either with metronidazole (MANOVA, F = 5.47, P-value < 10-5) 173 
or doxycycline (F = 3.86, P-value = 0.0013). Metronidazole treatment induced a transient peak in 174 
Proteobacteria in two out of five mice immediately after treatment with a relative abundance of up 175 
to 34.2%; however, this increase in Proteobacteria was not persistent following the recovery period. 176 
Interestingly, a mild longitudinal effect on phylum composition was also evident for the water 177 
control group (F = 2.25, P-value = 0.04), although no individual phyla differed significantly between 178 
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time points. Isotretinoin (F = 1.06, P-value = 0.403) and rapeseed oil (F = 1.199, P-value = 0.313) did 179 
not induce significant changes over time.  180 
3.2 Immediate and long-term effects on community composition 181 
The trends observed above at a very coarse resolution of phylum-level taxonomic composition were 182 
consistent at the level of individual unique sequences, i.e. the highest possible taxonomic resolution. 183 
Principal coordinate analysis of weighted UniFrac distances between samples calculated on a 184 
maximum likelihood phylogenetic tree at single nucleotide resolution are shown in Figure 3. Before 185 
treatment onset, phylogenetic community structure did not differ significantly between groups 186 
either for antibiotic (permutational multivariate analysis of variance as implemented in the ‘adonis’ 187 
function of the R package ‘vegan’; R2 = 0.1226, P-value = 0.107) or isotretinoin treatment (R2 = 188 
0.0442, P-value = 0.223). As expected, both antibiotic treatments led to significant shifts in 189 
community composition immediately after treatment relative to controls (R2 = 0.4499, P-value ≤ 190 
0.001); in particular, metronidazole treatment induced a distinct shift relative to both doxycycline-191 
treated mice (R2 = 0.479, P-value ≤ 0.001) and mice administered water only (R2 = 0.445, P-value ≤ 192 
0.001). The change in community composition of doxycycline-treated mice was less pronounced (R2 193 
= 0.252, P-value = 0.015). After the recovery period, community composition in doxycycline-treated 194 
mice remained significantly different from control mice (R2 = 0.115, P-value = 0.046). Interestingly, 195 
the observed changes in community composition directly after metronidazole treatment did not 196 
persist during the recovery period, with metronidazole-treated animals being indistinguishable from 197 
controls (R2 = 0.025, P-value = 0.73). In contrast, isotretinoin treatment did not lead to significant 198 
alterations in community composition either directly after treatment (R2 = 0.0435, P-value = 0.229) 199 
or after the recovery period (R2 = 0.0678, P-value = 0.384). 200 
3.3 Immediate and long-term effects on community richness and evenness 201 
Estimates of community richness and evenness assessed based on 98% average linkage OTUs using 202 
Chao’s Abundance based Coverage Estimator (ACE), the Gini-Simpson Index and the Shannon 203 
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entropy index (Figure 2B-D) supported a generally large intra-group variation in these parameters 204 
(Figure 4, left panel), and even shifts in diversity per animal over time based on paired observations 205 
were generally unspecific within a given treatment group (Figure 4, right panel). Directly after 206 
treatment, metronidazole induced a significant drop in community richness and evenness (ACE, 207 
Figure 4A, left panel; Shannon index, Figure 4C, left panel), in comparison to all other groups. The 208 
observed shift in Gini-Simpson index was not statistically significant. Similarly, directly after 209 
treatment, richness as estimated by ACE showed a significant fall in doxycycline-treated animals 210 
compared with isotretinoin-treated animals (P-value = 0.029), the water (P-value = 0.027) and 211 
rapeseed oil-treated (P-value = 0.003) controls (Figure 4A). Isotretinoin-treated mice showed 212 
significantly increased (P-value = 0.032) richness as estimated by the Gini-Simpson index relative to 213 
rapeseed oil-treated controls directly after treatment, which appeared to be due to a decrease in 214 
diversity in rapeseed oil-treated controls. No significant differences in richness or evenness were 215 
evident between any of the treatment groups after the recovery period. 216 
Changes in gut microbiota richness and evenness over time based on paired t-tests for 217 
individual animals are shown in Figure 4A-C (right panel). Treatment with metronidazole induced a 218 
significant fall in intra-animal evenness directly after treatment (Shannon index, P-value = 0.025), 219 
which recovered to pre-treatment richness levels (ACE, P-value = 0.034) and even more diverse 220 
composition (Shannon index, P-value ≤ 0.001) after the recovery period. Microbiota richness and 221 
evenness showed no significant change directly after treatment with doxycycline, but was 222 
significantly increased after the recovery period compared with directly after treatment (ACE, P-223 
value = 0.044; Gini-Simpson, P-value = 0.008; Shannon, P-value = 0.006) and pre-treatment (Gini-224 
Simpson, P-value = 0.033). Isotretinoin treatment did not induce any significant changes per animal 225 
over time. Interestingly, small but significant changes in gut microbiota evenness and richness were 226 
also seen in the vehicle-control groups over time. Relative to pre-treatment baseline, diversity 227 
showed a significant drop (Gini-Simpson, P-value = 0.008; Shannon, P-value = 0.013) in rapeseed oil 228 
controls directly after treatment, but recovered during the recovery period. In animals administered 229 
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water, there was a modest but significant increase (P-value = 0.043) in community richness 230 
(estimated by ACE) after the recovery period relative to pre-treatment levels, but otherwise there 231 
were no significant effects per animal over time. 232 
3.4 Identification of individual OTUs associated to treatment conditions 233 
To identify individual taxa-treatment associations, we quantified significant OTU abundance shifts 234 
per treatment relative to the respective vehicle-control group using the edgeR statistical framework 235 
[34]. The results of this analysis at different levels of taxonomic resolution per treatment group and 236 
time points are shown in Figure 5. Within the phylum Bacteroidetes, OTUs of the genera Alistipes sp., 237 
Marinilabilia sp. and 3 other Bacteroidales were highly abundant directly after the treatment period 238 
and this increase persisted after the recovery period. At the same time, we observed a pronounced 239 
decrease in OTUs of Clostridiales sp. and Lachnospiraceae sp. 240 
Treatment with doxycycline led to higher numbers of significantly over- or under-represented 241 
taxa in samples taken directly after the treatment period as well as in samples taken after the 242 
recovery period. In samples taken directly after the treatment period, 18 OTUs showed a significant 243 
increase in abundance and 33 OTUs showed a significant decrease in abundance. The greatest 244 
number of taxa with decreased abundance directly after doxycycline treatment was found within the 245 
phylum Firmicutes. Additionally, OTUs of the genera Ruminococcus sp. and Hespellia sp. were also 246 
less abundant directly after doxycycline exposure, a change that persisted during the recovery 247 
period. Moreover, after the recovery period in doxycycline-treated animals, 12 OTUs showed 248 
significantly increased abundance and 16 OTUs showed a significantly reduced abundance. Notably, 249 
the abundance of individual Butyrivibrio sp. and Proteobacteria sp. OTUs was found to be decreased 250 
after the recovery period, only, but not directly after doxycycline treatment. 251 
In metronidazole-treated animals, 20 OTUs (e.g. of Enterococcus gallianarium and 252 
Parabacteroides goldsteinii) were observed to be highly abundant directly after treatment while 11 253 
were less abundant (e.g. of Hespilia sp. and Ruminococcus sp.). Notably, 2 OTUs representing 254 
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Proteobacteria sp. were highly abundant in samples taken directly after treatment, corresponding to 255 
findings in this study for taxonomic composition by RDP classifier. Comparable with changes seen in 256 
community composition, richness and evenness, only 7 OTUs showed differential abundances during 257 
the recovery period. 258 
Isotretinoin treatment had a markedly less-pronounced effect on taxonomic composition than 259 
the other agents evaluated. Directly after the treatment period, only 8 classifiable OTUs showed a 260 
decrease in abundance (e.g. Bacteroides acidifaciens, Ruminococcus sp., Anaerotruncus sp.) relative 261 
to control animals with only a single OTU showing an increase in abundance (Lachnospiraceae sp). 262 
After the recovery period, no OTUs in isotretinoin-treated animals showed a significant change in 263 
abundance. 264 
Further analysis revealed that a number of individual OTUs showed persistent trends (e.g. B_01 265 
or F_04), particularly after treatment with doxycycline but less marked for metronidazole, suggesting 266 
an antibiotic-specific effect. Specifically, the abundance of Bacteroidetes OTUs (B_01, 02, 03, 05, 06) 267 
were elevated directly after doxycycline treatment as well as after the recovery period relative to 268 
control animals, while OTUs representing Firmicutes (F_03, 04, 07, 11) were less abundant for both 269 
time points. Following treatment with metronidazole, OTUs annotated for Bacteriodetes were 270 
specific; however, after the recovery period, change in B_01 and B_02 (increase) and in B_07 271 
(decrease) was the same as in doxycycline-treated animals. This finding could either indicate a 272 
common effect of both antibiotics or a potential time effect on these OTUs in the common 273 
reference, the water-treated mice. Moreover, the abundance of Firmicutes (F_02, 04, 05, 06, 08, 09, 274 
10) was decreased directly after the treatment period (comparable with doxycycline) but not after 275 
the recovery period. Interestingly, F_12 (Lachnospiraceae sp.) abundance was strongly decreased for 276 
both time points and for both antibiotics. Isotretinoin treatment showed no changes in OTUs 277 
common with those for the antibiotic groups. 278 
  14 
4. Discussion 279 
In this study, we have shown differential effects of antibiotics and isotretinoin on the gut microbiota 280 
that support a putative association between doxycycline treatment, but not metronidazole or 281 
isotretinoin, and IBD development. Overall, metronidazole induced a significant drop in diversity 282 
directly following treatment, which returned to pre-treatment status during the recovery period. In 283 
contrast, doxycycline induced only modest effects on diversity directly following treatment but a 284 
persistent impact on composition after the recovery period, whereas isotretinoin had no significant 285 
impact on community composition, richness or evenness either directly after treatment or after 286 
recovery. 287 
Distinct changes in gut microbiota composition have been reported in IBD patients [36] and in 288 
animal models of colitis alterations in gut microbiota composition are associated with increased 289 
disease risk and severity [37]. A history of bacterial gastrointestinal infections and antibiotic 290 
treatment is reported to severely affect the intestinal microbiota and to be associated with the 291 
development of gastrointestinal disorders such as IBD in children and adults [10, 12]. 292 
Recent studies have shown metronidazole, a nitroimidazole-based antibiotic frequently 293 
prescribed for gastrointestinal-related disorders, including IBD, to be strongly associated with new-294 
onset IBD (odds ratio 5.01) [12, 38] and doxycycline to be associated with CD (odds ratio 2.25) [11]. A 295 
putative association to IBD has also been reported for isotretinoin, a treatment for severe acne [11]. 296 
Confirmation of the putative association between isotretinoin and IBD has proved difficult due to 297 
confounding antibiotic treatment and limited evidence on a potential immunogenic response to 298 
commensal gut microbiota triggered by isotretinoin, or any long-term persistent effects on the gut 299 
microbiota. This led us to investigate mouse fecal microbial composition before and directly after a 300 
treatment course with metronidazole, doxycycline or isotretinoin as well as following a recovery 301 
period. 302 
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In animal models, metronidazole treatment has provided contradictory findings, e.g. 303 
compromised goblet cell function, decreased mucus layer thickness and increased microbial 304 
stimulation of the epithelium as well as increased susceptibility to Citrobacter rodentium infection in 305 
mice [39], and an increase in mucus layer thickness in rats [38]. In the present study, metronidazole 306 
treatment was associated with pronounced changes in community composition and significant 307 
reduction in bacterial richness and evenness directly after treatment, which recovered during 308 
recovery phase. This finding is seemingly at odds with the reported strong association of 309 
metronidazole with new-onset IBD [12]. However, the increases in Proteobacteria and the 310 
facultative anaerobic species (e.g. Enterococcus spp.), marked reduction in Clostridiales and 311 
relatively modest impact on Bacteroides was in accordance with the inherent specificity of 312 
metronidazole. Jakobsson et al. [15] reported an increase in Enterococcus spp. and Proteobacteria 313 
(Klebsiella) and a reduction in Lachnospiraceae spp. in human samples, while Sjölund et al. [40] 314 
showed persistence of resistant Enterococci for up to 3 years. A recent study investigating the effect 315 
of metronidazole on microbiota composition in a model of elderly colonic fermentation identified a 316 
very pronounced shift in gut microbiota composition.  Clostridium cluster IV, F. prausnitzii and 317 
Roseburia spp. were the bacterial groups particularly affected by metronidazole treatment with 318 
incomplete recovery after 10 days without treatment. [41]. Despite the pronounced alteration of gut 319 
microbiota composition directly after metronidazole treatment in our study, only seven OTUs 320 
remained significantly altered post recovery. Five of these (B_01, B_02, F_07, F_12, F_13) were 321 
similarly impacted after the recovery period in doxycycline-treated animals. It might be 322 
hypothesized, therefore, that some strains are particularly sensitive to treatment with antibiotics 323 
(F_07, F_12), or are opportunistic to a disturbed microbiota (B_01, B_02, F_13). However, it is also 324 
possible that there is a potential time effect on these OTUs in the common reference, the water-325 
treated animals. An increase or decrease of these OTUs in the water-treated group would skew the 326 
abundances in both treatment groups (doxycycline and metronidazole) since they are compared 327 
with each other. 328 
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In the present study, doxycycline was associated with only moderate changes in microbiota 329 
richness and evenness immediately after treatment but, based on taxonomic composition analysis, a 330 
strong shift mainly in Clostridiales (up to 500-fold down-regulation), with only a few strains of the 331 
Firmicutes phylum showing marked increase in abundance, e.g. Clostridium fusiformis and 332 
Lactobacillus murinus. Directly after treatment with doxycycline, Firmicutes strains were reduced 333 
whereas Bacteroidetes showed a distinct pattern of OTUs that were either increased or decreased in 334 
abundance; possibly mirroring the sensitivity of individual strains towards doxycycline. As the gut 335 
microbiota is a complex ecosystem with networks of co-dependence between different strains, any 336 
niche resulting from a reduction in Firmicutes, for example, will very likely be re-occupied by other 337 
strains. The findings here, in fact, confirm the overall reduction in Firmicutes reported recently in 338 
patients suffering from Q-fever endocarditis administered long-term doxycycline and 339 
hydrochloroquine [42]. Notably, we did not see the reduction in Bacteroidetes reported by Angelakis 340 
et al., representing the only other study investigating the effect of doxycycline on the gut microbiota 341 
[42]. Tetracyclines have been used as animal growth promoting agents in productive livestock for 342 
several decades and the impact on gut microbiota composition has been reviewed recently [43, 44]. 343 
Most studies  investigated the impact of low-dose chlortetracycline in pigs. Zhang et al. show an 344 
increase in the phylum Firmicutes and the genus Prevotella [45] while Holman et al. observed only 345 
minor alterations with sub-therapeutic doses of chlortetracycline [46]. A study investigating the 346 
impact of combined administration of chlortetracycline and sulfamethazine on the bovine gut 347 
microbiota did not identify any differences in bacterial community fingerprints or bacterial load in 348 
comparison to the control group [47] 349 
In our study, complete recovery of the microbiota was not observed even by 4 weeks following 350 
cessation of doxycycline treatment: The treatment groups showed little differentiation in community 351 
richness or evenness but changes in OTU-abundances. Overall community composition remained 352 
different from controls, most notably Bacteroides OTUs elevated directly after treatment, remained 353 
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elevated post recovery (B_01,02,03,05,06) whereas those Firmicutes OTUs, reduced directly after 354 
treatment (F_03,04,07,11,12) remained so by 4 weeks after cessation of treatment. 355 
Such persistent changes at OTU level might be speculated to promote the development of 356 
colitis in a susceptible host. To date, reduction in diversity, temporal instability and over- (e.g. 357 
Desulfovibrio) or under-representation (e.g. Faecalibacterium prausnitzii) of individual strains have 358 
been shown in UC and new-onset CD In addition, decreased abundance of the genera 359 
Faecalibacterium, Roseburia and Clostridiales, and increased abundance of Enterobacteriaceae, are a 360 
consistent finding in CD patients [36, 48]. Thus, our findings of a persistent reduction of Clostridiales 361 
OTUs are congruent with these reported alterations in microbiota in CD patients. Nevertheless, 362 
further investigations are needed to establish a causal relationship. 363 
In summary, these findings demonstrate differential effects of antibiotics on gut microbiota 364 
community composition and diversity, with doxycycline mediating long-term changes in the murine 365 
gut microbiota. In contrast, the microbiota profile of isotretinoin-treated animals was not 366 
significantly affected, providing no evidence that isotretinoin impacts the risk for IBD development 367 
through effects on the gut microbiota.368 
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Figure Legends 509 
Figure 1. Experimental design. (A) BALB/c female mice were treated with isotretinoin, rapeseed oil 510 
(isotretinoin vehicle), metronidazole, doxycycline or water (antibiotics vehicle) daily by oral gavage 511 
for 2 weeks. Fecal samples were collected before treatment, after two weeks of treatment 512 
(immediate effects) and after a recovery phase of four weeks post-treatment cessation (long-term 513 
effects). (B) For isotretinoin and rapeseed oil, 16 animals per group were sampled before and 514 
immediately after treatment, and 8 animals were sampled after the recovery phase. For 515 
metronidazole, doxycycline and water, 5–12 animals were sampled per time point and group. (C) No 516 
differences within treatment groups were registered with respect to body weight over all time 517 
points.  518 
Figure 2. Phylum-level taxonomic composition and diversity of the gut microbiota per mouse. (A) 519 
Relative abundances of the four dominant phyla per animal, treatment and time point, as 520 
determined using the ribosomal database project Classifier with default settings. Phylum-level 521 
taxonomic composition showed minor variations within groups, where Bacteroidetes and Firmicutes 522 
were the dominant phyla. (B-D) Per-animal diversity (alpha diversity), indicating the differences in 523 
community richness and evenness per mouse across time points and treatments. (B) ACE; (C) Gini-524 
Simpson index; (D) Shannon index; all indices calculated based on 98% average linkage OTUs.  525 
Figure 3. Analysis of microbiota community composition. Pairwise weighted UniFrac distances 526 
between samples were mapped to two-dimensional space using principal coordinates analysis for 527 
visualization. Individual samples are shown as filled circles, per-group centroids as filled squares; axis 528 
labels indicate the percent variance explained per principal coordinate. The upper panel shows 529 
animals treated with water (dark blue), doxycycline (green) or metronidazole (orange). The lower 530 
panel shows animals treated with isotretinoin (red) or rapeseed oil (light blue). Shifts in community 531 
composition between groups per time point were tested using permutational multivariate analysis 532 
of variance, as implemented in the ‘adonis’ function of the R package vegan). R2 values correspond 533 
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to an effect size of between-group differences in community composition, whereas P-values indicate 534 
significance based on a permutation test (n = 1’000).  535 
Figure 4. Effects on community richness and evenness (‘alpha diversity’). Left panel: ACE (A), Gini-536 
Simpson (B) and Shannon (C) indices are shown per time point and treatment; differences between 537 
groups were assessed using one-way analysis of variance (data not shown), followed by unpaired, 538 
two-sided t-tests. Right panel: within-group comparisons of per-animal diversity, relative to before-539 
treatment levels; each point indicates the absolute shift of diversity in a given animal with respect to 540 
time point 0. Significance of shifts was assessed using paired, two-sided t-tests, also for comparisons 541 
of per-mouse levels immediately upon treatment to post-recovery (indicated as dashed brackets).  542 
Figure 5. Identification of individual OTUs associated with treatment conditions using differential 543 
abundance analysis. For each time point and treatment group, differentially abundant OTUs with 544 
respect to control groups (i.e. animals treated with water or rapeseed oil, respectively) were 545 
detected using edgeR, at a false discovery rate of α < 0.001. Significantly differential OTUs are 546 
shown, colored by phylum, sorted by log2 (fold change) in abundance relative to control levels (x-547 
axis). Species-level taxonomic annotations were obtained, where possible, by assigning OTU 548 
representative sequences to their closest BLAST hit against the National Center for Biotechnology 549 
Information’s 16S rRNA database, at a tolerance of 97% identity. Individual OTUs with significant 550 
abundance shifts for several groups or time points are indicated using running numbers per phylum 551 
(B_01, B_02, etc.). 552 
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